SCHEMBL4911692

SCHEMBL4911692

CCC(CC)(CC)OC(=O)c1ccc(Br)c(OC)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B2 P37059 1/20 0.46
ALDH1A1 P00352 2/20 0.44
KDM4E B2RXH2 1/20 0.43
POLB P06746 1/20 0.43
TSHR P16473 3/20 0.43
MAPT P10636 2/20 0.42
MAPK1 P28482 1/20 0.42
HDAC6 Q9UBN7 1/20 0.40
CYP1A2 P05177 3/20 0.40
CYP2C19 P33261 2/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40
NCOA1 Q15788 1/20 0.40
NCOA3 Q9Y6Q9 1/20 0.40
CYP2D6 P10635 1/20 0.39
HPGD P15428 1/20 0.39
NOTUM Q6P988 1/20 0.39
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4909001 0.86 EGFR (0.39) HSD17B2ALDH1A1KDM4EPOLBTSHR
SCHEMBL2592630 0.83 ALDH1A1 (0.47) HSD17B2ALDH1A1KDM4EPOLBTSHR
SCHEMBL4904728 0.81 HSD17B2 (0.44) HSD17B2KDM4EPOLBTSHRMAPT
SCHEMBL4909129 0.80 SMN1; SMN2 (0.48) ALDH1A1KDM4EPOLBMAPTHDAC6
SCHEMBL426745 0.79 MAPT (0.62) HSD17B2ALDH1A1KDM4ETSHRMAPT
SCHEMBL25606750 0.78 ALDH1A1 (0.51) HSD17B2ALDH1A1KDM4EPOLBTSHR
SCHEMBL28114733 0.76 ALDH1A1 (0.72) ALDH1A1TSHRMAPTMAPK1HDAC6
SCHEMBL5368592 0.74 CYP1A2 (0.45) ALDH1A1KDM4EMAPK1CYP1A2CYP2C19
SCHEMBL12982799 0.74 LMNA (0.55) ALDH1A1POLBTSHRHDAC6CYP1A2
SCHEMBL644265 0.74 CA12 (0.69) ALDH1A1KDM4ETSHRMAPK1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080076760-A1 2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION WAKAMOTO PHARMACEUTICAL CO., LTD (JP) 2008-03-27 US disclosed
EP-1820799-A1 2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION Wakamoto Pharmaceutical Co., Ltd. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080076760-A1 2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION GABRA5, GABRA1, GABRB1 HSD17B2 110/4885ALDH1A1 492/4885KDM4E 2138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.